These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25058337)
1. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337 [TBL] [Abstract][Full Text] [Related]
2. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479 [TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era. Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478 [TBL] [Abstract][Full Text] [Related]
4. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era. Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580 [TBL] [Abstract][Full Text] [Related]
5. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Batty N; Ghonimi E; Feng L; Fayad L; Younes A; Rodriguez MA; Romaguera JE; McLaughlin P; Samaniego F; Kwak LW; Hagemeister FB Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):15-8. PubMed ID: 23137719 [TBL] [Abstract][Full Text] [Related]
6. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ; Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398 [TBL] [Abstract][Full Text] [Related]
7. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma]. Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203 [No Abstract] [Full Text] [Related]
8. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499 [TBL] [Abstract][Full Text] [Related]
9. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. Marcheselli R; Bari A; Tadmor T; Marcheselli L; Cox MC; Papotti R; Ferrari A; Baldini L; Gobbi P; Levy I; Pugliese G; Federico M; Polliack A; Pozzi S; Sacchi S Hematol Oncol; 2020 Oct; 38(4):439-445. PubMed ID: 32495944 [TBL] [Abstract][Full Text] [Related]
10. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705 [TBL] [Abstract][Full Text] [Related]
11. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567 [TBL] [Abstract][Full Text] [Related]
12. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens. Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331 [TBL] [Abstract][Full Text] [Related]
13. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Lin B; Chen C; Qian Y; Feng J Leuk Lymphoma; 2015; 56(9):2563-8. PubMed ID: 25686648 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255 [TBL] [Abstract][Full Text] [Related]
15. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584 [TBL] [Abstract][Full Text] [Related]
18. Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. Chae YS; Shin H; Sohn SK; Lee SJ; Moon JH; Kang BW; Kim JG; Yang DH; Lee JJ; Park TI Leuk Lymphoma; 2012 Sep; 53(9):1757-63. PubMed ID: 22372848 [TBL] [Abstract][Full Text] [Related]
19. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Bento L; Díaz-López A; Barranco G; Martín-Moreno AM; Baile M; Martín A; Sancho JM; García O; Rodríguez M; Sánchez-Pina JM; Novelli S; Salar A; Bastos M; Rodríguez-Salazar MJ; González de Villambrosia S; Córdoba R; García-Recio M; Martínez-Serra J; Del Campo R; Luzardo H; García D; Hong A; Abrisqueta P; Sastre-Serra J; Roca P; Rodríguez J; Gutiérrez A; Br J Haematol; 2020 Mar; 188(6):888-897. PubMed ID: 31782146 [TBL] [Abstract][Full Text] [Related]
20. Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma. Yoo C; Kim S; Sohn BS; Kim JE; Yoon DH; Huh J; Lee DH; Kim SW; Lee JS; Suh C Korean J Intern Med; 2010 Sep; 25(3):301-8. PubMed ID: 20830228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]